CG Oncology, Inc. (CGON)

Compare

22.05

-2.44

(-9.96%)

At close: April 1 at 4:00:01 PM EDT

22.24

+0.19

+(0.86%)

After hours: April 1 at 6:44:28 PM EDT

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks yesterday

CGON
-9.96%
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology’s clinical trial program, including translational data, planned - IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for pa

GlobeNewswire yesterday

CGON
-9.96%
Company News for Mar 31, 2025

Companies In The News Are: LULU, BRZE, AIR, CGON.

Zacks yesterday

BRZE

AIR

CGON
-9.96%
CG Oncology Full Year 2024 Earnings: Misses Expectations

CG Oncology ( NASDAQ:CGON ) Full Year 2024 Results Key Financial Results Net loss: US$88.0m (loss widened by 30% from...

Simply Wall St. 3 days ago

CGON
-9.96%
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Mi

GlobeNewswire 4 days ago

CGON
-9.96%
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025?

We recently published a list of the 12 Best IPO Stocks to Buy in 2025. In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against other best IPO stocks to buy in 2025. On February 25, Hamilton Lane co-CEO Erik Hirsch joined ‘Closing Bell Overtime’ on CNBC […]

Insider Monkey 6 days ago

CGON
-9.96%
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that

GlobeNewswire 8 days ago

CGON
-9.96%
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

Late-breaking clinical and first translational data from BOND-003 Cohort C will be presentedIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a late-breaking abstract on BOND-003 Cohort C, as well as three posters highlighting cretostimogene grenadenorepvec, will be pres

GlobeNewswire 20 days ago

CGON
-9.96%
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET. Interested parties can access

GlobeNewswire last month

CGON
-9.96%
Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now?

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against the other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the […]

Insider Monkey last month

CGON
-9.96%
Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field, Head of European Pharma Research at […]

Insider Monkey last month

CGON
-9.96%
Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against other most oversold healthcare stocks to buy now. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising […]

Insider Monkey last month

CGON
-9.96%
CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62%

Key Insights Given the large stake in the stock by institutions, CG Oncology's stock price might be vulnerable to their...

Simply Wall St. last month

CGON
-9.96%
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

Zacks last month

ANIP

CGON
-9.96%
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?

The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 2 months ago

CGON
-9.96%
How to Navigate the Stock and Bond Markets in 2025

We asked 10 investing and economic experts for their recommendations as Donald Trump returns to power. Here’s what they said.

The Wall Street Journal 2 months ago

CGON
-9.96%
AMZN

KOS
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000

GlobeNewswire 3 months ago

CGON
-9.96%
CG Oncology Announces Pricing of Public Offering

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at

GlobeNewswire 3 months ago

CGON
-9.96%
CG Oncology Announces Proposed Public Offering

IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 7,300,000 shares of its common stock. Additionally,

GlobeNewswire 3 months ago

CGON
-9.96%
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBCSCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a

GlobeNewswire 3 months ago

CGON
-9.96%

Performance Overview

Return	CGON	S&P 500 (^GSPC)
YTD	-23.12%	-4.23%
1-Year	-48.43%	+7.42%
3-Year	-23.97%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CG Oncology, Inc. (CGON)

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

Company News for Mar 31, 2025

CG Oncology Full Year 2024 Earnings: Misses Expectations

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025?

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now?

Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts

Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now

CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62%

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect?

How to Navigate the Stock and Bond Markets in 2025

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Performance Overview